Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018.
Latvia
PCV10
S. pneumoniae serotype replacement
invasive pneumococcal disease
pneumococcal conjugate vaccine (PCV)
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
10
2020
accepted:
21
07
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
In 2010 in Latvia, invasive pneumococcal disease (IPD) became a cause for concern and vaccination of infants with four doses of 7-valent pneumococcal conjugate vaccine (PCV7) commenced. In 2012, 10-valent pneumococcal conjugate vaccine (PCV10) (three doses at 2, 4, and 12-15 month of age) vaccination was introduced. We described incidence and serotype distribution of IPD in Latvia and investigated serotypes associated with death from IPD based on surveillance data. Adult vaccination against pneumococcal infection is not included in the national immunization program. Laboratory confirmed IPD cases are passively notified to the Center for Disease Prevention and Control of Latvia (CDPC) by laboratories and clinicians. We calculated incidence by age, sex, case fatality, and trend in serotypes by conducting a retrospective population-based cross-sectional study based on national IPD surveillance data. From 2012 to 2018 466 cases of IPD were reported. The highest notified incidence was in 2015 at 4.4/100,000, which fell to 3.9 in 2018. The highest mean annual IPD incidence was in infants (4.8) and in the elderly (6.0). PCV10 vaccine serotypes were the most prevalent in IPD cases up to 2015 with a decreasing trend from 50% (20/40) in 2012 to 19% (14/74) in 2018 (chi2 test for trend of odds = 0.000). PCV23nonPCV13 vaccine serotypes had an increasing trend and rose from 18% (7/40) to 34% (25/74) (chi2 test for trend of odds = 0.000). Non-Vaccine serotypes had an increasing trend and rose from 13% (5/40) to 27% (20/74) (chi2 test for trend of odds = 0.038). Reported total case fatality was 19% (87/466). The highest, at 36% (20/56), was reported in 2013. After adjusting for age,
Identifiants
pubmed: 34692599
doi: 10.3389/fped.2021.532489
pmc: PMC8529945
doi:
Types de publication
Journal Article
Langues
eng
Pagination
532489Informations de copyright
Copyright © 2021 Savrasova, Krumina, Cupeca, Zeltina, Villerusha, Grope, Viksna, Dimina and Balasegaram.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Infect Dis. 2015 Oct 14;15:419
pubmed: 26468008
Thorax. 2019 May;74(5):473-482
pubmed: 30355641
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-12
pubmed: 27996380
Infect Chemother. 2013 Dec;45(4):351-66
pubmed: 24475349
Expert Rev Vaccines. 2017 Jun;16(6):625-640
pubmed: 28409537
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Expert Rev Vaccines. 2017 Oct;16(10):1007-1027
pubmed: 28783380
Eur J Clin Microbiol Infect Dis. 2007 May;26(5):303-10
pubmed: 17457623
Eur J Pediatr. 2014 Apr;173(4):469-76
pubmed: 24221605
Expert Rev Vaccines. 2018 Jun;17(6):479-493
pubmed: 29241390
Vaccine. 2013 Mar 1;31(11):1529-34
pubmed: 23261044
Hum Vaccin Immunother. 2016 Aug 2;12(8):2124-2134
pubmed: 27096714
Vaccine. 2007 Apr 20;25(16):3085-9
pubmed: 17287048
Int J Infect Dis. 2010 Mar;14(3):e197-209
pubmed: 19700359
Vaccine. 2012 Jul 6;30(32):4717-8
pubmed: 22621828
Am J Med. 2018 Jan;131(1):100.e1-100.e7
pubmed: 28803139
BMC Infect Dis. 2012 Sep 07;12:207
pubmed: 22954038